Near-Infrared Fluorescence Imaging with Indocyanine Green for Robot-Assisted Partial Nephrectomy: A Systematic Review
Carlo Giulioni1, Prashant Motiram Mulawkar2,3,4, Daniele Castellani1
1Urology Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60121 Ancona, Italy.
Cancers
|December 9, 2023
Summary
Near-infrared fluorescence (NIRF) with indocyanine green (ICG) during robot-assisted partial nephrectomy (RAPN) improves kidney function but does not affect cancer outcomes. NIRF-ICG is recommended for nephron preservation in kidney tumor patients.
Area of Science:
- Urology
- Surgical Oncology
- Medical Imaging
Background:
- Kidney tumors (KT) often necessitate partial nephrectomy (PN) to preserve renal function.
- Robot-assisted partial nephrectomy (RAPN) is a minimally invasive approach for KT treatment.
- Near-infrared fluorescence (NIRF) imaging with indocyanine green (ICG) is being explored to enhance surgical precision during RAPN.
Purpose of the Study:
- To analyze the impact of NIRF using ICG on perioperative and long-term outcomes in patients undergoing RAPN for KT.
- To evaluate the effectiveness of NIRF-ICG in improving functional and oncological results during RAPN.
Main Methods:
- A comprehensive literature search was conducted on PubMed, EMBASE, and Scopus up to September 12, 2023.
- Included observational studies comparing RAPN with and without NIRF-ICG in KT patients.
- Meta-analysis of perioperative outcomes (e.g., warm ischemia time, postoperative eGFR) and oncological outcomes (e.g., positive surgical margins, recurrence rates).
Main Results:
- Eight prospective studies involving 535 patients were analyzed (212 in ICG group, 323 in No ICG group).
- The NIRF-ICG group demonstrated a significantly shorter warm ischemia time (WMD = -2.05, p=0.011) and improved postoperative eGFR (WMD = 7.67, p=0.002).
- No significant differences were observed in other perioperative outcomes, positive surgical margins, or tumor recurrence rates between the groups.
Conclusions:
- NIRF with ICG during RAPN significantly improves functional outcomes, specifically reducing warm ischemia time and enhancing postoperative kidney function.
- NIRF-ICG does not appear to influence oncological outcomes, such as positive surgical margins or tumor recurrence rates.
- NIRF-ICG is a valuable adjunct in RAPN when the primary goal is nephron preservation and maintaining renal function.


